Despite positive news this week regarding its COVID-19 vaccine, AstraZeneca shares dropped due to concerns about side effects and market competitiveness. The news Monday regarding AstraZeneca (NYSE:AZN)'s trial of coronavirus vaccine AZD1222 seemed to be the type of information that would push a stock's price up, not down. Interim results from the phase 1/2 trial…
Published: July 20, 2020 at 4:13 a.m. ET Shares of Enzymatica ENZY, +63.70% jumped 67% in Stockholm as the company said preliminary results show the ability of the mouth spray ColdZyme, in vitro, to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic. The study demonstrated that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3%, the company said.…
(Reuters) - Synairgen Plc (SYNG.L) said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdom, sending its shares skyrocketing. The trial, which used interferon beta, showed that patients who were given Synairgen’s formulation…
Moderna's shares soared after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine.Moderna's stock rose more than 16% in after-hours trading on the news. All…
Shares in Sun International [JSE:SUI] plunged over 7% in early morning trade after receiving an unsolicited bid by a Chilean investment company to buy a controlling stake in the owner of Sun City and other casino operations in the country.Sun International put out a statement on Thursday hitting out at a purported offer saying it is "neither…
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.